Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

[1]  H. Levin,et al.  Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. , 1996, Urology.

[2]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[3]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[4]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[5]  H. Neuwirth,et al.  Patterns of positive specimen margins and detectable prostate specific antigen after radical perineal prostatectomy. , 1995, The Journal of urology.

[6]  A. Pollack,et al.  Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. , 1995, Urology.

[7]  D. Paulson.  Impact of radical prostatectomy in the management of clinically localized disease. , 1994, The Journal of urology.

[8]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[9]  M. Toublanc,et al.  Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. , 1994, Urology.

[10]  D. Bostwick,et al.  Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. , 1994, The Journal of urology.

[11]  A. Zietman,et al.  Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. , 1994, The Journal of urology.

[12]  N. Olson,et al.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. , 1993, The Journal of urology.

[13]  S. Cha,et al.  Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[15]  A. V. von Eschenbach,et al.  Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy , 1993, Cancer.

[16]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[17]  A W Partin,et al.  Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. , 1993, The Journal of urology.

[18]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[19]  I. Kaplan,et al.  Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. , 1993, The Journal of urology.

[20]  P. Humphrey,et al.  Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. , 1993, The Journal of urology.

[21]  E. Messing,et al.  Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. K. Harris,et al.  Survivorship Analysis for Clinical Studies , 1990 .

[23]  J. Epstein.  Evaluation of Radical Prostatectomy Capsular Margins of Resection: The Significance of Margins Designated as Negative, Closely Approaching, and Positive , 1990, The American journal of surgical pathology.

[24]  T. Stamey,et al.  Positive surgical margins at radical prostatectomy: importance of the apical dissection. , 1990, The Journal of urology.

[25]  W. Catalona,et al.  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. , 1990, The Journal of urology.